4-{3-[(Pyridin-4-ylmethyl)amino]-[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}phenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulator

Hepatocellular carcinoma is the most common type of primary liver Cancer. However, multidrug resistance (MDR) is a major obstacle to the effective chemotherapy of Cancer cells. This report documents the rational design, synthesis, and biological evaluation of a novel series of triazolotriazines substituted with CH₂ NH-linked pyridine for use as dual c-Met/MDR inhibitors. Compound 12g with IC₅₀ of 3.06 μM on HepG2 cells showed more potency than crizotinib (IC₅₀ = 5.15 μM) in the MTT assay. In addition, 12g inhibited c-Met kinase at a low micromolar level (IC₅₀ = 0.052 μM). 12g significantly inhibited P-gp and MRP1/2 efflux pumps in both cancerous HepG2 and BxPC3 cells starting from the lower concentrations of 3 and 0.3 µM, respectively. 12g did not inhibit MDR1 and MRP1/2 in noncancerous H69 cholangiocytes up to the concentration of 30 and 60 µM, respectively. Current results highlighted that cancerous cells were more susceptible to the effect of 12g than normal cells, in which the inhibition occurred only at the highest concentrations, suggesting a further interest in 12g as a selective Anticancer agent. Overall, 12g, as a dual c-Met and P-gp/MRP inhibitor, is a promising lead compound for developing a new generation of Anticancer agents.

MDR1; MRP1/2; c-Met kinase inhibitor; multidrug resistance; triazolotriazine.